Co-Owned Pipeline
Through co-owned partnerships, risk, cost and IP are shared within strategic R&D alliances with pharma and biotech as well as academic drug discovery centers. The aim of these partnerships is to develop R&D projects faster and more efficiently based on knowledge sharing. This ensures a quicker ROI and access to a far larger and more comprehensive knowledge base than has ever been possible before.
Co-owned Pipeline – Evolution From Discovery Into Clinical-Stage Projects
Since the inception of Action Plan 2012, Evotec has followed the principle of sharing risk and ownership. Moving forward, Evotec will continue this model with its partners within Action Plan 2025 and stick to its long-term strategy of co-owning assets, but typically will not sponsor clinical trials.
Over the last decade, Evotec’s co-owned pipeline rose from approx. 10 to 150 plus, which is a result of the company’s unique business strategy. Building a co-owned pipeline takes time, and the last few years can be almost seen as a seeding phase for the first wave of precision medicine therapeutic candidates for the portfolio. The next 12–24 months are likely to show an increased number of clinical projects for multiple, key therapeutic areas.
>90
Small molecule assets
>20
Biologics assets
>10
Cell & gene therapy assets
>10
Multiple modality assets
>90
Small molecule assets
>20
Biologics assets
>10
Cell & gene therapy assets
>10
Multiple modality assets
Logic for Co-Ownership Model
- Flow of milestones and royalties-based revenues to accelerate profitability
- Protection of P&L against development attrition
- Upside participation in clinical and commercial-stage assets allows Evotec to focus on high-quality research and development activities
In recent years, Evotec has laid a strong foundation for a continued and strong growth of its co-owned pipeline. Early-stage programs will continuously flow into the pipeline through own R&D, partnerships, Equity and BRIDGEs, but it is Evotec’s clear vision and goal to significantly broaden the clinical pipeline and have the first approved drugs in its portfolio.
Different Sources for Co-Ownership That Continuously Fill the Pipeline
Three entry doors open the paths to the largest co-owned pipeline that has ever been built in this industry.
- Platforms
e.g. High-value integrated drug discovery & development; Data-driven precision medicine - Indication-driven target pipelines
- BRIDGEs, operational ventures Equity/ royalty ownership in companies via operational venture capital investment
e.g. LAB282, Exscientia, Topas, Breakpoint, …
With very focused R&D investments we have generated a meaningful revenue line. These R&D payments and milestones have resulted in an EBITDA line fluctuating around the zero line – this does not take into account future products on the market delivering royalty-based income. At the same time, the number of potential co-owned product opportunities is increasing substantially and continues to grow.
The pipeline of more than 150 co-owned assets already holds the potential of a massive pool of milestones today with the first royalties and larger later stage milestones coming in.
Explore our pipeline by therapeutic area or by research phase.
